CoChat

Targeting integrin pathways: mechanisms and advances in therapy

Open access
Pang, Xiaocong, He, Xu, Qiu, Zhiwei, Zhang, Hanxu, Xie, Ran, Liu, Zhiyan, Gu, Yanlun, Zhao, Nan, Xiang, Qian, Cui, Yimin · 2023 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 598 of the 598 references it cites were found in a registry or an index.

Abstract

Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mechanisms, including protein-protein interactions, conformational changes, and trafficking. Due to their exposure on the cell surface and sensitivity to the molecular blockade, integrins have been investigated as pharmacological targets for nearly 40 years, but given the complexity of integrins and sometimes opposite characteristics, targeting integrin therapeutics has been a challenge. To date, only seven drugs targeting integrins have been successfully marketed, including abciximab, eptifibatide, tirofiban, natalizumab, vedolizumab, lifitegrast, and carotegrast. Currently, there are approximately 90 kinds of integrin-based therapeutic drugs or imaging agents in clinical studies, including small molecules, antibodies, synthetic mimic peptides, antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, imaging agents, etc. A serious lesson from past integrin drug discovery and research efforts is that successes rely on both a deep understanding of integrin-regulatory mechanisms and unmet clinical needs. Herein, we provide a systematic and complete review of all integrin family members and integrin-mediated downstream signal transduction to highlight ongoing efforts to develop new therapies/diagnoses from bench to clinic. In addition, we further discuss the trend of drug development, how to improve the success rate of clinical trials targeting integrin therapies, and the key points for clinical research, basic research, and translational research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-01259-6

Cites

598 of 598 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Timeline of the historical milestone for the study of integrin receptors and their main antagonists and agents in the past four decades
Fig. 1 Timeline of the historical milestone for the study of integrin receptors and their main antagonists and agents in the past four decadesCC BY · PubMed Central
Fig. 2 The primary structure and representative conformations of integrins. a Organization of domains within the primary structures. b Arrangement of domains within the representative 3D crystal structure of integrins. c Conformational change of integrins: bent closed, extended–closed, and extended open conformations
Fig. 2 The primary structure and representative conformations of integrins. a Organization of domains within the primary structures. b Arrangement of domains within the representative 3D crystal structure of integrins. c Conformational change of integrins: bent closed, extended–closed, and extended open conformationsCC BY · PubMed Central
Fig. 3 Classification, distribution, and ligands of integrins. The inner ring shows the 24 integrins that are composed of 17 α subunits and 8 β subunits. They are divided into four categories, namely, RGD-binding integrins, leukocyte cell-adhesion integrins, collagen-binding integrins, and laminin-binding integrins, according to their distribution, ligand specificity, and functions. The middle ring shows the distribution of integrins in different cell types. The outer ring indicates the ligands bound by different types of integrins
Fig. 3 Classification, distribution, and ligands of integrins. The inner ring shows the 24 integrins that are composed of 17 α subunits and 8 β subunits. They are divided into four categories, namely, RGD-binding integrins, leukocyte cell-adhesion integrins, collagen-binding integrins, and laminin-binding integrins, according to their distribution, ligand specificity, and functions. The middle ring shows the distribution of integrins in different cell types. The outer ring indicates the ligands bound by different types of integrinsCC BY · PubMed Central
Fig. 4 Schematic overview of integrin activation-associated signaling cascades. Integrin activation is regulated by multiple external signals, such as ECM, mechanotransduction or signaling from non-ECM ligands, including growth factor receptors, hormones, and small molecules, which is termed the “outside-in” mechanism. ECM or non-ECM ligand binding and force application results in integrin clustering and initiates downstream signaling to the actin cytoskeleton through recruited talin and vinculin, where actin can simultaneously pull on integrins and further in turn promote force generation. The “outside-in” mechanism then triggers various signaling cascades that ultimately result in cell survival, proliferation, cell spreading, and even tumorigenesis and metastasis. On the plasma membrane, there is also an “inside-out” mechanism, which regulates the displacement of intracellular integrin inhibitors and allows talin or kindlin binding to integrin β-tails, controlling integrin affinity for ECM components. For example, in neutrophils, both Talin-1 and Kindlin-3 are rapidly recruited to activate β2 integrins induced by extracellular chemokines binding to GPCR (G-protein-coupled receptor). Solid arrows indicate activation, the dotted line indicates recruiting, and the solid blunt end arcs indicate inhibitory effects
Fig. 4 Schematic overview of integrin activation-associated signaling cascades. Integrin activation is regulated by multiple external signals, such as ECM, mechanotransduction or signaling from non-ECM ligands, including growth factor receptors, hormones, and small molecules, which is termed the “outside-in” mechanism. ECM or non-ECM ligand binding and force application results in integrin clustering and initiates downstream signaling to the actin cytoskeleton through recruited talin and vinculin, where actin can simultaneously pull on integrins and further in turn promote force generation. The “outside-in” mechanism then triggers various signaling cascades that ultimately result in cell survival, proliferation, cell spreading, and even tumorigenesis and metastasis. On the plasma membrane, there is also an “inside-out” mechanism, which regulates the displacement of intracellular integrin inhibitors and allows talin or kindlin binding to integrin β-tails, controlling integrin affinity for ECM components. For example, in neutrophils, both Talin-1 and Kindlin-3 are rapidly recruited to activate β2 integrins induced by extracellular chemokines binding to GPCR (G-protein-coupled receptor). Solid arrows indicate activation, the dotted line indicates recruiting, and the solid blunt end arcs indicate inhibitory effectsCC BY · PubMed Central
Fig. 5 The expression and function of major integrins and their related cancer types and metastatic sites. The expression of integrins can vary considerably between normal and tumor tissue and is also associated with cancer types and organotrophic metastasis
Fig. 5 The expression and function of major integrins and their related cancer types and metastatic sites. The expression of integrins can vary considerably between normal and tumor tissue and is also associated with cancer types and organotrophic metastasisCC BY · PubMed Central
Fig. 6 Roles of integrins in fibrosis processes in NASH, PH, and ADPKD. The lower part of the circle shows the role of integrins in liver fibrosis in NASH. In hepatic cells (HCs), activated integrin α9β1 is endocytosed by hepatocytes and secreted in the form of extracellular vesicles (EVs), which are further captured by MoMFs. Captured integrin α9β1 mediates MoMF adhesion to liver sinusoidal endothelial cells (LSECs) by binding to VCAM-1, which accelerates liver fibrosis. In HSCs, integrin α8β1 promotes liver fibrosis by activating TGF-β. The binding of integrin αvβ3 with OPN could promote laminin and α-SMA expression, which causes ECM accumulation and fibrosis progression. Integrin αvβ5 also binds with OPN and enhances liver fibrosis, but the underlying mechanism still needs to be clarified. In CD4 + T cells, the adhesion between integrin α4β7 and HC expressing MAdCAM-1 recruits CD4 + T cells to the liver, which induces liver inflammation and fibrosis. The left part of the circle shows the role of integrins in intimal fibrosis in PH. In the progression of PH, integrin α1, α8, αv, β1, and β3 are upregulated, and α5 is downregulated in PASMCs. Integrin α1 increases and α5 decreases the concentration of Ca2 + , promoting intimal fibrosis. The binding between integrin αvβ3 and OPN activates FAK signal transduction, which might be involved in the processes of vascular remodeling. The right part of the circle shows the role of integrins in renal fibrosis in ADPKD. Integrin αvβ3 expressed in renal tubular epithelial cells binds with periostin, activating TGF-β and promoting renal fibrosis. Binding between integrin αvβ3 and OPN is also involved in the renal fibrosis process, but the underlying mechanism is unclear. Renal tubular epithelial cells expressing integrin β1 enhance the expression of collagen, fibronectin, and α-SMA, which promote renal fibrosis
Fig. 6 Roles of integrins in fibrosis processes in NASH, PH, and ADPKD. The lower part of the circle shows the role of integrins in liver fibrosis in NASH. In hepatic cells (HCs), activated integrin α9β1 is endocytosed by hepatocytes and secreted in the form of extracellular vesicles (EVs), which are further captured by MoMFs. Captured integrin α9β1 mediates MoMF adhesion to liver sinusoidal endothelial cells (LSECs) by binding to VCAM-1, which accelerates liver fibrosis. In HSCs, integrin α8β1 promotes liver fibrosis by activating TGF-β. The binding of integrin αvβ3 with OPN could promote laminin and α-SMA expression, which causes ECM accumulation and fibrosis progression. Integrin αvβ5 also binds with OPN and enhances liver fibrosis, but the underlying mechanism still needs to be clarified. In CD4 + T cells, the adhesion between integrin α4β7 and HC expressing MAdCAM-1 recruits CD4 + T cells to the liver, which induces liver inflammation and fibrosis. The left part of the circle shows the role of integrins in intimal fibrosis in PH. In the progression of PH, integrin α1, α8, αv, β1, and β3 are upregulated, and α5 is downregulated in PASMCs. Integrin α1 increases and α5 decreases the concentration of Ca2 + , promoting intimal fibrosis. The binding between integrin αvβ3 and OPN activates FAK signal transduction, which might be involved in the processes of vascular remodeling. The right part of the circle shows the role of integrins in renal fibrosis in ADPKD. Integrin αvβ3 expressed in renal tubular epithelial cells binds with periostin, activating TGF-β and promoting renal fibrosis. Binding between integrin αvβ3 and OPN is also involved in the renal fibrosis process, but the underlying mechanism is unclear. Renal tubular epithelial cells expressing integrin β1 enhance the expression of collagen, fibronectin, and α-SMA, which promote renal fibrosisCC BY · PubMed Central
Fig. 7 Main roles of integrins in the process of AS. Integrin signaling can affect multiple processes in AS, including endothelial dysfunction and activation, leukocyte homing to the plaque, smooth muscle cell migration, and thrombosis. In the process of endothelial cell activation, ox-LDL activates α5β1, induces the FAK/ERK/p90RSK pathway and promotes NF-κB signaling. Shear stress can activate αvβ3 and induce PAK activation by binding to fibronectin, thereby promoting NF-κB activation. Both ox-LDL and shear stress generated by blood flow mediate the increased expression of proinflammatory genes (ICAM-1 and VCAM-1) after integrin ligation. During the process of leukocyte homing to plaques, αxβ2 and α4β1 interact with VCAM-1 on the endothelial cell surface, and αxβ2 and αLβ2 interact with ICAM-1 to promote leukocyte adhesion. Integrins α4β1, α9β1 and αvβ3 on the surface of monocytes interact with osteopontin, which is expressed in atherosclerotic plaques, to promote monocyte migration and survival. Integrin αDβ2 is upregulated during macrophage foam cell formation. During vascular smooth muscle cell migration, αvβ3 binding with fibronectin, osteopontin, etc., mediates FAK activity and drives migration. In the process of thrombosis, integrins α2β1 and aIIbβ3 on platelets are involved in platelet adhesion, activation, aggregation, and thrombosis
Fig. 7 Main roles of integrins in the process of AS. Integrin signaling can affect multiple processes in AS, including endothelial dysfunction and activation, leukocyte homing to the plaque, smooth muscle cell migration, and thrombosis. In the process of endothelial cell activation, ox-LDL activates α5β1, induces the FAK/ERK/p90RSK pathway and promotes NF-κB signaling. Shear stress can activate αvβ3 and induce PAK activation by binding to fibronectin, thereby promoting NF-κB activation. Both ox-LDL and shear stress generated by blood flow mediate the increased expression of proinflammatory genes (ICAM-1 and VCAM-1) after integrin ligation. During the process of leukocyte homing to plaques, αxβ2 and α4β1 interact with VCAM-1 on the endothelial cell surface, and αxβ2 and αLβ2 interact with ICAM-1 to promote leukocyte adhesion. Integrins α4β1, α9β1 and αvβ3 on the surface of monocytes interact with osteopontin, which is expressed in atherosclerotic plaques, to promote monocyte migration and survival. Integrin αDβ2 is upregulated during macrophage foam cell formation. During vascular smooth muscle cell migration, αvβ3 binding with fibronectin, osteopontin, etc., mediates FAK activity and drives migration. In the process of thrombosis, integrins α2β1 and aIIbβ3 on platelets are involved in platelet adhesion, activation, aggregation, and thrombosisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 598 references

Research works printed but not linked: 5

  1. Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151–155 (2002). · DOI · Paper page
  2. Hamidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533–548 (2018). · DOI · Paper page
  3. Eke, I. et al. β1Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J. Clin. Invest. 122, 1529–1540 (2012). · DOI · Paper page
  4. Arthos, J. et al. The role of integrin α(4)β(7) in HIV pathogenesis and treatment. Curr. HIV/AIDS Rep. 15, 127–135 (2018). · DOI
  5. Li, J. et al. Novel pure αVβ3 integrin antagonists that do not induce receptor extension, prime the receptor, or enhance angiogenesis at low concentrations. ACS Pharmacol. Transl. Sci. 2, 387–401 (2019). · DOI

Cited by

See all 1,275

Metadata

Authors
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y.
Affiliations
Peking University First Hospital (CN)
Corresponding author
  • Xiang, Qian
  • Cui, Yimin
Venue
Signal Transduction and Targeted Therapy
Published
2023-01-02
Volume
8
Issue
1
Pages
1-1
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4313382384
Cited by
1,275
References
598
Citations by year
2026: 323 · 2025: 608 · 2024: 265 · 2023: 78
FWCI
50.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (No. 81903714, No. 81973320)
  • Ministry of Science and Technology of the People’s Republic of China (No. 2020YFC2008304)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
integrins, integrin-targeted therapy, integrin signaling, integrin regulation, integrin inhibitors, antibody-drug conjugates, CAR T-cell therapy
MeSH terms
Cell Adhesion, Cell Communication, Peptides, Signal Transduction, Integrins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting integrin pathways: mechanisms and advances in therapy. https://app.cochat.ai/papers/10.1038/s41392-022-01259-6
The paper
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023). Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-01259-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.